As a result, the majority of genomic alterations are distinct between squamous (e.g., cyclin dependent kinase inhibitor 2A (CDKN2A) and tumor protein p53 (TP53)) and adenocarcinoma (e.g., KRAS proto‐oncogene (KRAS) and epidermal growth factor receptor (EGFR)) NSCLC.7 The gene discussed is TP53; the disease is adenocarcinoma.